Bimzelx is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe plaque psoriasis. Bimzelx is also referred to by its drug name bimekizumab-bkzx.
Bimzelx is a type of biologic drug. It is a dual interleukin (IL)- 17A and IL-17F inhibitor. Bimzelx is believed to work by targeting specific proteins in the immune system and reducing inflammation.
How do I take it?
Bimzelx is injected subcutaneously every four weeks for the first 16 weeks and then every four to eight weeks depending on instructions from a doctor.
Bimzelx is available in a single-dose prefilled syringe or autoinjector.
The FDA-approved label for Bimzelx lists common side effects including upper respiratory infections, oral thrush, headache, fungal infections, and stomach flu.
Rare but serious side effects listed for Bimzelx include suicidal ideation and behaviors, infection, liver abnormalities, and inflammatory bowel disease.
For more details about this treatment, visit:
Prescribing Information: Bimzelx — UCB